Literature DB >> 16117787

Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.

Janet A Fairley1, Chang Ling Fu, George J Giudice.   

Abstract

Bullous pemphigoid (BP) is a subepidermal blistering disease characterized by autoantibodies against the hemidesmosomal protein BP180 (BPAg2, type XVII collagen). NC16A, a non-collagenous stretch of the BP180 ectodomain, is the primary target of pathogenic immunoglobulin (Ig)G autoantibodies and IgE class autoantibodies. This study further characterized the IgE-reactive regions of BP180. Of the ten sera from untreated BP patients, eight contained IgE reactive with the entire BP180 ectodomain. The IgE in four of these eight sera reacted with NC16A, whereas in the remaining four sera IgE immunoreactivity was restricted to sites downstream of NC16A. In contrast, IgG reactivity to NC16A was detected in nine of the ten BP sera, and in the remaining serum, IgG, as well as IgE, reacted exclusively with non-NC16A sites on the BP180 ectodomain. Fine mapping of the antigenic sites within NC16A revealed very similar reactivity patterns for IgE and IgG, with NC16A subregion-2 being the major site recognized by both isotypes. Eight of the untreated BP patients were tested for histamine release from their basophils in response to NC16A. Antigen-specific histamine release was observed only in those patients with detectable circulating IgE directed against NC16A (three of eight). Future studies will investigate the pathogenic relevance of anti-BP180 IgE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117787     DOI: 10.1111/j.0022-202X.2005.23853.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  25 in total

1.  Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8.

Authors:  Françoise Van den Bergh; Steven L Eliason; Brian T Burmeister; George J Giudice
Journal:  Exp Dermatol       Date:  2012-08       Impact factor: 3.960

Review 2.  Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease.

Authors:  Ye Qian; Donna A Culton; Joseph S Jeong; Nicole Trupiano; Jesus G Valenzuela; Luis A Diaz
Journal:  Autoimmun Rev       Date:  2016-07-08       Impact factor: 9.754

3.  Detection of serum IgE class anti-SSA antibodies in mothers with foetal loss.

Authors:  Iwao Sekigawa; Kazuhiko Kaneda; Hiroshi Kaneko; Yoshinari Takasaki; Kenji Takamori; Hideoki Ogawa
Journal:  Rheumatol Int       Date:  2007-12-19       Impact factor: 2.631

Review 4.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

Review 5.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

6.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

7.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

Review 8.  Mast cells and immunological skin diseases.

Authors:  Daniel Navi; Jun Saegusa; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 9.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

10.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Authors:  Kelly A N Messingham; Megan H Noe; Marisa A Chapman; George J Giudice; Janet A Fairley
Journal:  J Immunol Methods       Date:  2009-05-05       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.